In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Growth

Set Alert for Growth

Pandemic Leaves Medtech With $500bn In M&A Firepower

EY’s M&A Firepower report predicts very active M&A activity for medtechs in 2021, driven by diagnostics and digital health, but with some headwinds remaining.

Business Strategies Commercial

J.P. Morgan Highlights: Pricing Reforms, Digital Tech And COVID

The annual J.P. Morgan Health Care Conference has come to a close. In Vivo has summarized some of the key themes to appear from 2021’s virtual meeting of industry leaders, investors and technology creators.

Artificial Intelligence Business Strategies

Medtech Has Hope For A Solid Recovery Later In 2021

Delivering innovation is still the driving force for medtechs intent on growing in the market, regardless of COVID-19, the disruptive effects of which have intensified with the appearance of new variants, says Jefferies Healthcare equity analyst Raj Denhoy.

Business Strategies Commercial

Snapshot: December Highlights

A selection of articles you might have missed from November and December 2020, including exclusive interviews with industry leaders and a deeper dive into COVID-19's impact on R&D.

Business Strategies Commercial

Mogrify: Using Big Data To Transform Development Of Cell Therapies

Money in the bank, biotech legacies onboard, a fresh partnership, an emerging internal cell therapy pipeline and a grand vision for the broad-scale application of its technology – has Mogrify got it all? The biotech’s chief business officer, Karin Schmitt, talks to In Vivo about the group’s near- and long-term goals.

C-Suite Speaks Commercial

Journey East: How Chinese Returnees Build Global-Bound Biopharmas

As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.

Asia Pacific China

Into 2021 Medtechs Prioritize Third-Wave Coronavirus Readiness

Coronavirus has definitively changed health care delivery and the perceptions of health technologies and digital ecosystems. Industry will need to adjust to the aftermath of COVID-19, take opportunities and learn lessons from 2020 or 2021 could be every inch as challenging.

Commercial Companies

Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19

2019 saw fewer revenue-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.

Business Strategies Commercial

Numbers Crunched: Reviewing Biopharma's FY 2019 Performance

The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?

Business Strategies Companies

Pfizer Holds Number One Spot And Takeda Breaks The Top 10

Takeda's acquisition of Shire fueled the company into a top 10 pharma company in the latest Scrip 100 rankings, as other mega-mergers are set to shape the leaderboard in the future. 

Business Strategies Commercial

Pandemic Spotlights Tensions Between Profit And Philanthropy

The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.

Business Strategies Commercial

The Golden Winged Warbler And Creating Pharma Supply Chain Immunity

Supply chain expert outlines to In Vivo how pharma can create resilient and secure supply chains and some benefits of localization.

Manufacturing India
See All
UsernamePublicRestriction

Register